|

F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus

RECRUITINGPhase 1Sponsored by Shandong New Time Pharmaceutical Co., LTD
Actively Recruiting
PhasePhase 1
SponsorShandong New Time Pharmaceutical Co., LTD
Started2025-10-30
Est. completion2027-12-31
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted

Summary

The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA. Through a dual-targeting mechanism, it aims to guide the body's own immune system to target and kill B cells and plasma cells that overexpress BCMA.Based on the application of B cell depletion strategies in the treatment of autoimmune diseases, as well as the exploration of similar drugs in autoimmune diseases, we speculate that F182112 is also effective for autoimmune diseases. Therefore, we plan to carry out clinical research of F182112 in patients with systemic lupus erythematosus, with the aim of bringing more treatment options to patients.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Age 18-65 years, any gender;
2. Diagnosed with systemic lupus erythematosus (SLE) ≥12 weeks according to the classification criteria established by the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR);
3. Able to understand the trial procedures and content, and voluntarily sign the informed consent form.

Exclusion Criteria:

1. Previously received BCMA-targeted therapy;
2. Received any B-cell depletion therapy (such as anti-CD20, anti-CD19, etc.) or anti-plasma cell therapy within 6 months before starting the drug or within 5 half-lives (whichever is longer);

Conditions2

LupusSystemic Lupus Erythematosus (SLE)

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.